A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection

Last updated: February 26, 2026
Sponsor: Mirum Pharmaceuticals, Inc.
Overall Status: Active - Not Recruiting

Phase

2/3

Condition

Hepatitis

Liver Disorders

Treatment

Brelovitug 900 mg

Delayed Treatment with Brelovitug 300mg

Brelovitug 300 mg

Clinical Study ID

NCT06907290
BJT-778-301
  • Ages > 18
  • All Genders

Study Summary

This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection. The comparator in this study will be 24-weeks of delayed treatment. During the 24-weeks of delayed treatment, participants will complete the same visits and assessments as those randomized to initiate brelovitug immediately. At the completion of 24-week delayed treatment period, all participants will start treatment with brelovitug.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Willing and able to provide written informed consent.

  • Chronic HDV infection

  • HDV RNA >500 IU/mL at Screening.

  • Abnormal ALT (>upper limit of normal) at Screening.

  • Willing to take or already taking HBV nucleos(t)ide therapy

Exclusion

Exclusion Criteria:

  • Pregnant or nursing females.

  • Unwilling to comply with contraception requirements during the study.

  • Difficulty with blood collection and/or poor venous access for the purposes ofphlebotomy

  • Presence of other liver disease(s) (does not include HBV or HDV infection) such asnon-alcoholic steatohepatitis (NASH), alcohol associated hepatitis, cholestaticliver disease, hepatocellular carcinoma.

  • Clinical hepatic decompensation (i.e., ascites, encephalopathy variceal hemorrhage).

  • Solid organ or bone marrow transplantation Note: other protocol definedInclusion/Exclusion criteria may apply.

Study Design

Total Participants: 150
Treatment Group(s): 3
Primary Treatment: Brelovitug 900 mg
Phase: 2/3
Study Start date:
March 25, 2025
Estimated Completion Date:
September 30, 2029

Study Description

Study will consist of 3 study arms. Approximately 150 participants will be randomized 2:2:1 to one of the following treatment arms:

  • Arm 1: Participants randomized to Arm 1 will receive brelovitug 300 mg subcutaneously once weekly.

  • Arm 2: Participants randomized to Arm 2 will receive brelovitug 900 mg subcutaneously once every 4 weeks.

  • Arm 3: Participants randomized to Arm 3 will attend study clinic visits and delay treatment with brelovitug. At Week 24, all participants will receive brelovitug 300 mg subcutaneously once weekly.

Connect with a study center

  • 102 Melbourne

    Melbourne, Victoria
    Australia

    Site Not Available

  • 101 Camperdown

    Camperdown,
    Australia

    Site Not Available

  • 104 Liverpool

    Liverpool,
    Australia

    Site Not Available

  • 703 Sliven

    Sliven, Silven 8800
    Bulgaria

    Site Not Available

  • 705 Plovdiv

    Plovdiv,
    Bulgaria

    Site Not Available

  • 702 Bulgaria

    Sofia,
    Bulgaria

    Site Not Available

  • 706 Sofia

    Sofia,
    Bulgaria

    Site Not Available

  • Sofia

    Sofia,
    Bulgaria

    Active - Recruiting

  • 706 Sofia

    Sofia 727011,
    Bulgaria

    Site Not Available

  • 704 Stara Zagora

    Stara Zagora,
    Bulgaria

    Site Not Available

  • 233 Calgary

    Calgary, Calgary
    Canada

    Site Not Available

  • 233 Calgary

    Calgary 5913490, Calgary
    Canada

    Site Not Available

  • 234 Alberta

    Edmonton, Edmonton T6G 2G5
    Canada

    Site Not Available

  • 234 Alberta

    Edmonton 5946768, Edmonton T6G 2G5
    Canada

    Site Not Available

  • 231 Toronto

    Toronto, Ontario
    Canada

    Site Not Available

  • 235 Montreal

    Montreal, Quebec
    Canada

    Site Not Available

  • 181 Tbilisi

    Tbilisi, 0105
    Georgia

    Site Not Available

  • 182 Tbilisi

    Tbilisi,
    Georgia

    Site Not Available

  • 183 Tbilisi

    Tbilisi, 0105
    Georgia

    Site Not Available

  • Tbilisi

    Tbilisi, 0105
    Georgia

    Active - Recruiting

  • 181 Tbilisi

    Tbilisi 611717, 0105
    Georgia

    Site Not Available

  • 182 Tbilisi

    Tbilisi 611717,
    Georgia

    Site Not Available

  • 212 Haifa

    Haifa, Haifa District
    Israel

    Site Not Available

  • 212 Haifa

    Haifa 294801, Haifa District 294800
    Israel

    Site Not Available

  • 211 Israel

    Beersheba,
    Israel

    Site Not Available

  • 901 Chisinau

    Chisinau,
    Moldova

    Site Not Available

  • 001 Auckland

    Auckland,
    New Zealand

    Site Not Available

  • 221 Karachi City

    Karachi, Karachi
    Pakistan

    Site Not Available

  • 221 Karachi City

    Karachi 1174872, Karachi
    Pakistan

    Site Not Available

  • 291 Belgrade

    Belgrade, Belgrade
    Serbia

    Site Not Available

  • 291 Belgrade

    Belgrade 792680, Belgrade
    Serbia

    Site Not Available

  • 191 Istanbul

    Istanbul, Istanbul
    Turkey (Türkiye)

    Site Not Available

  • 191 Istanbul

    Istanbul 745044, Istanbul 745042
    Turkey (Türkiye)

    Site Not Available

  • 110 Kyiv

    Kyiv, 01001
    Ukraine

    Site Not Available

  • 247 Garden Grove

    Garden Grove, California 92840
    United States

    Site Not Available

  • 242 Huntington Beach

    Huntington Beach, California 92647
    United States

    Site Not Available

  • 252 Long Beach

    Long Beach, California 90805
    United States

    Site Not Available

  • 244 Los Angeles

    Los Angeles, California 90033
    United States

    Site Not Available

  • 250 Miami

    Miami, Florida 33166
    United States

    Site Not Available

  • 251, Illinois

    Chicago, Illinois 60612
    United States

    Site Not Available

  • 248 Lowa

    Cities in Iowa, Iowa 52242
    United States

    Site Not Available

  • Lowa

    Cities in Iowa, Iowa 52242
    United States

    Active - Recruiting

  • 254 Baltimore

    Baltimore, Maryland 21287
    United States

    Site Not Available

  • 241, Massachusetts

    Boston, Massachusetts 02114
    United States

    Site Not Available

  • 245 New York

    New York, New York 10007
    United States

    Site Not Available

  • 253 New York

    New York, New York 10075
    United States

    Site Not Available

  • 255 New York

    New York, New York 10075
    United States

    Site Not Available

  • 256 New York

    New York, New York 10065
    United States

    Site Not Available

  • 253 New York

    New York 5128581, New York 5128638 10075
    United States

    Site Not Available

  • 255 New York

    New York 5128581, New York 5128638 10075
    United States

    Site Not Available

  • 256 New York

    New York 5128581, New York 5128638 10065
    United States

    Site Not Available

  • 257 Philadelphia

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

  • 249 San Antonio

    San Antonio, Texas 78215
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.